Antigenics to Report Earnings On July 25, 2002; Conference Call to Follow.

Business Editors & Health/Medical Writers

BIOWIRE2K

Antigenics Inc. (NASDAQ: AGEN) will release its second quarter 2002 financial results before the market opens on July 25, 2002.

Antigenics executives, including Chairman and CEO Garo Armen, Ph.D., and Chief Medical Officer Jonathan Lewis, M.D., Ph.D., will host a conference call at 11:00 ET that same day. To access the live call, dial [phone] (U.S.) or [phone] (international). A replay will be available approximately two hours after the call through midnight ET on August 8, 2002. The replay number is [phone] (U.S.) or [phone] (international), and the access code is 4801744. The replay will also be available on the company's website approximately two hours after the live call.

Antigenics' mission is to develop superior health care products that enhance and extend human lives for a wide range of cancers, infectious diseases, and autoimmune and degenerative disorders. The company's cancer portfolio includes Oncophage(R), a personalized cancer vaccine in Phase III trials and on the U.S. Food and Drug Administration's Fast Track development program for kidney cancer and melanoma; and two liposomal products in Phase II development: Aroplatin(TM), a third-generation platinum chemotherapeutic, and ATRA-IV, a form of vitamin A. Other products in development include QS-21, an immune adjuvant being tested in several advanced clinical vaccine programs in partnership with leading pharmaceutical companies, and AG-702, a genital herpes immunotherapeutic agent in Phase I testing. For more information about Antigenics, please visit www.antigenics.com.